1800-272-662
Shopping Cart 0
countryflagAU
Login

Invion Ltd

Healthcare AU IVX

0.079AUD
0.003(3.95%)

Last update at 2026-03-13T00:25:00Z

Day Range

0.080.08
LowHigh

52 Week Range

0.070.14
LowHigh

Fundamentals

  • Previous Close 0.08
  • Market Cap7.37M
  • Volume2539
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-5.15814M
  • Revenue TTM0.00301M
  • Revenue Per Share TTM-
  • Gross Profit TTM -1.48777M
  • Diluted EPS TTM-0.14

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -8.80773M -5.62777M -1.61482M -2.24138M -1.48295M
Minority interest - - - - -
Net income -8.80773M -5.62777M -1.61482M -2.24138M -1.48295M
Selling general administrative 2.02M 1.33M 1.62M 2.40M 1.79M
Selling and marketing expenses 0.69M 4.53M - - -
Gross profit -1.29028M 1.00M 1.21M 0.97M 0.81M
Reconciled depreciation 4.81M 0.82M 0.68M 0.42M 0.28M
Ebit -8.81075M -5.38776M -1.64847M -2.32143M -1.57234M
Ebitda -3.99615M -4.57175M -0.96537M -1.89901M -1.29447M
Depreciation and amortization 4.81M 0.82M 0.68M 0.42M 0.28M
Non operating income net other - - - - -
Operating income -5.28643M -5.67720M -1.64847M -2.24143M -1.57234M
Other operating expenses 5.29M 9.37M 0.04M 0.89M 0.77M
Interest expense 0.69M 0.24M - 0.00005M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.69M 0.24M 0.03M 0.00005M 0.00009M
Net interest income -0.69478M -0.24000M 0.03M 0.00005M 0.00009M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -0.00000M 0.05M -0.00005M -0.00009M
Total revenue 0.00000M 3.69M 4.10M 3.29M 2.33M
Total operating expenses 4.00M 8.56M 5.75M 5.61M 3.90M
Cost of revenue 1.29M 2.69M 2.90M 2.32M 1.52M
Total other income expense net -3.52130M 0.05M 0.08M 0.08M 0.09M
Discontinued operations - - - - -
Net income from continuing ops -8.80773M -5.62777M -1.61482M -2.24138M -1.48295M
Net income applicable to common shares -8.80773M -5.62777M -1.61482M -2.24138M -1.48295M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 9.49M 15.45M 19.05M 20.04M 5.64M
Intangible assets 8.54M - 13.23M 11.39M 4.57M
Earning assets - - - - -
Other current assets 0.08M 0.09M - 0.03M 0.03M
Total liab 1.24M 1.01M 0.65M 0.46M 0.85M
Total stockholder equity 8.25M 14.44M 18.40M 19.58M 4.79M
Deferred long term liab - - - - -
Other current liab - 0.29M 0.25M 0.24M 0.40M
Common stock - 148.35M 146.88M 146.54M 130.96M
Capital stock 151.21M - 146.88M 146.54M 130.96M
Retained earnings -144.54139M -136.08009M -130.47522M -130.83604M -128.59466M
Other liab - - - - -
Good will - - - - -
Other assets - 0.00000M - - -
Cash 0.85M 0.78M 4.08M 8.47M 1.04M
Cash and equivalents - - - 8.47M 1.04M
Total current liabilities 1.24M 1.01M 0.65M 0.46M 0.85M
Current deferred revenue - - - - 0.01M
Net debt - -0.78353M -4.08490M -8.47344M -1.03682M
Short term debt - - - 0.00000M -0.01100M
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity - - -16.40793M -15.70762M -2.36146M
Property plant equipment - - 0.06M 0.00048M 0.00102M
Total current assets 0.93M 2.08M 5.76M 8.65M 1.08M
Long term investments - - - - -
Net tangible assets - - 5.17M 8.19M 0.23M
Short term investments - - - - -
Net receivables - 1.21M 1.62M 0.14M 0.01M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.54M 0.72M 0.40M 0.22M 0.45M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 2.16M 1.99M 3.87M 2.43M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 13.33M -13.28633M -11.39360M -4.56602M
Deferred long term asset charges - - - - -
Non current assets total 8.56M 13.37M 13.29M 11.39M 4.57M
Capital lease obligations - - - - -
Long term debt total - - - 0.00000M 0.00000M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments 0.00000M -0.90000M -2.57583M -7.25000M -
Change to liabilities - - 0.16M -0.38907M 0.49M
Total cashflows from investing activities 0.00000M -0.90000M -2.57583M -7.25000M -7.25000M
Net borrowings -0.74441M - - - -
Total cash from financing activities 3.04M 0.00000M 15.80M 15.80M 15.80M
Change to operating activities - - 0.02M 0.02M -0.01825M
Net income -8.80773M -5.62777M -1.61482M -2.24138M -1.48295M
Change in cash 0.07M -3.30138M -4.38854M 7.44M 0.42M
Begin period cash flow 0.78M 4.08M 8.47M 1.04M 0.62M
End period cash flow 0.85M 0.78M 4.08M 8.47M 1.04M
Total cash from operating activities -2.96884M -2.40138M -1.81270M -1.10890M 0.42M
Issuance of capital stock 3.95M - - 16.64M -
Depreciation 4.81M 0.82M 0.68M 0.42M 0.28M
Other cashflows from investing activities - -0.90000M - - 0.00000M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -0.00532M -2.46578M -1.50149M -0.13798M 0.25M
Sale purchase of stock -0.17030M - -0.84198M -0.84198M -0.84198M
Other cashflows from financing activities 1.45M -0.90000M -2.57583M -7.25000M -7.25000M
Change to netincome - - 0.43M 1.21M 0.90M
Capital expenditures 0.00000M 0.90M 2.58M 7.25M 7.25M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.02M -2.44201M -1.50149M -0.13798M 0.25M
Stock based compensation 0.09M 0.23M 0.37M 0.96M 0.90M
Other non cash items 0.91M 4.62M -0.88099M 0.71M 1.62M
Free cash flow -2.96884M -3.30138M -4.38854M -8.35890M 0.42M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IVX
Invion Ltd		 0.003 3.95% 0.08 - - 7.32 1.29 6.88 -25.5842
AFP
Aft Pharmaceuticals Ltd		 - -% 3.00 23.08 19.88 1.35 3.81 1.72 13.67
VLS
Vita Life Sciences Ltd		 -0.02 0.80% 2.48 13.89 42.73 1.46 2.42 1.24 6.53
SNT
Syntara Ltd		 -0.001 3.33% 0.03 - 20.45 6.32 4.62 6.32 -2.1607
MVP
Medical Developments International Ltd		 0.005 1.23% 0.41 - 166.67 1.14 0.83 0.75 11.48

Reports Covered

Stock Research & News

View All

Profile

Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical trial to treat non-melanoma skin cancer, as well as for the treatment of oesophageal cancer. The company has collaborations with Hudson Institute of Medical Research, Peter MacCallum Cancer Centre, Dr. I&B Co., Ltd., and Hanlim Pharm Co., Ltd. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

Invion Ltd

385 Bourke Street, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Mr. Thian Chew Exec. Chairman & CEO NA
Ms. Melanie Jaye Leydin B.Bus, C.A., CA Chief Financial Officer 1973
Dr. Dean Naylor Head of Intellectual Property Devel. NA
Ms. Claire Newstead-Sinclair BBus, C.A., CA Company Sec. NA
Mr. Thian Chew Executive Chairman & CEO NA
Ms. Melanie Jaye Leydin B.Bus, C.A. Chief Financial Officer 1973
Dr. Dean Naylor Head of Intellectual Property Development NA
Ms. Claire Newstead-Sinclair BBus, C.A., CA Company Secretary NA
Mr. Thian Chew Executive Chairman & CEO NA
Ms. Melanie Jaye Leydin B.Bus, C.A. Chief Financial Officer 1973

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.